Literature DB >> 21796327

Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety.

Marian K Rippy1, Denise Zarins, Neil C Barman, Andrew Wu, Keith L Duncan, Christopher K Zarins.   

Abstract

BACKGROUND: Renal sympathetic hyperactivity is associated with hypertension, a leading cause of mortality worldwide. Renal sympathetic denervation via the Symplicity Catheter System has been shown to decrease blood pressure by 33/11 mmHg by 6 months, with no radiofrequency (RF)-related adverse sequelae visible by CT/MR angiography or renal duplex ultrasound 6 months after the procedure. Here, we present preclinical work predating those clinical results. We performed therapeutic renal sympathetic denervation in a swine animal model to characterize the vascular safety and healing response 6 months after renal denervation therapy.
METHODS: In December 2007, seven domestic swine received a total of 32 radiofrequency ablations via the Symplicity Catheter System and were euthanatized 6 months later. Renal angiography was done before, immediately after, and 6 months after procedure. The renal vessels were examined histologically with H&E and Movat pentachrome stains to identify evidence of vascular and neural injury. The kidneys and urinary system were also examined for evidence of gross and microscopic abnormalities.
RESULTS: Renal nerve injury involved primarily nerve fibrosis, replacement of nerve fascicles with fibrous connective tissue, and thickening of the epineurium and perineurium. Renal arterial findings included fibrosis of 10-25% of the total media and underlying adventitia, with mild disruption of the external elastic lamina. No significant smooth muscle hyperplasia or inflammatory components were observed. There was no renal arterial stenosis or thrombosis observed by angiography or histology. No gross or microscopic device-related abnormalities were noted in the kidney, surrounding stroma, or urinary bladder.
CONCLUSIONS: In a swine model, renal denervation via the Symplicity Catheter System resulted in no clinically significant adverse renal artery or renal findings 6 months after the procedure. This is corroborated by the vascular safety profile demonstrated in subsequent human clinical studies.

Entities:  

Mesh:

Year:  2011        PMID: 21796327     DOI: 10.1007/s00392-011-0346-8

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  17 in total

1.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

2.  Antihypertensive pharmacotherapy: adverse effects of medications promote nonadherence.

Authors:  Icilma V Fergus
Journal:  J Cardiometab Syndr       Date:  2009

Review 3.  Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover.

Authors:  M Esler; G Jennings; P Korner; I Willett; F Dudley; G Hasking; W Anderson; G Lambert
Journal:  Hypertension       Date:  1988-01       Impact factor: 10.190

4.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

Review 5.  Translational medicine: the antihypertensive effect of renal denervation.

Authors:  Gerald F DiBona; Murray Esler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-02       Impact factor: 3.619

6.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

7.  The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management.

Authors:  Murray Esler
Journal:  J Appl Physiol (1985)       Date:  2009-11-25

8.  Hypertension treatment and control in five European countries, Canada, and the United States.

Authors:  Katharina Wolf-Maier; Richard S Cooper; Holly Kramer; José R Banegas; Simona Giampaoli; Michel R Joffres; Neil Poulter; Paola Primatesta; Birgitta Stegmayr; Michael Thamm
Journal:  Hypertension       Date:  2003-11-24       Impact factor: 10.190

9.  Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation.

Authors:  Markus P Schlaich; Elisabeth Lambert; David M Kaye; Zygmunt Krozowski; Duncan J Campbell; Gavin Lambert; Jacqui Hastings; Anuradha Aggarwal; Murray D Esler
Journal:  Hypertension       Date:  2003-11-10       Impact factor: 10.190

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more
  38 in total

Review 1.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

2.  Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry.

Authors:  Britta Vogel; Michael Kirchberger; Martin Zeier; Felicitas Stoll; Benjamin Meder; Daniel Saure; Martin Andrassy; Oliver J Mueller; Stefan Hardt; Vedat Schwenger; Anna Strothmeyer; Hugo A Katus; Erwin Blessing
Journal:  Clin Res Cardiol       Date:  2013-10-15       Impact factor: 5.460

Review 3.  The biophysics of renal sympathetic denervation using radiofrequency energy.

Authors:  Hitesh C Patel; Paramdeep S Dhillon; Felix Mahfoud; Alistair C Lindsay; Carl Hayward; Sabine Ernst; Alexander R Lyon; Stuart D Rosen; Carlo di Mario
Journal:  Clin Res Cardiol       Date:  2014-05       Impact factor: 5.460

4.  Early reduction of therapy-resistant hypertension in a patient after single-sided renal denervation approach.

Authors:  Marco R Schroeter; Michael Koziolek
Journal:  Clin Res Cardiol       Date:  2013-11-19       Impact factor: 5.460

Review 5.  Cardiac innervation and sudden cardiac death.

Authors:  Keiichi Fukuda; Hideaki Kanazawa; Yoshiyasu Aizawa; Jeffrey L Ardell; Kalyanam Shivkumar
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

6.  [Renal denervation. Current developments].

Authors:  A Saleh
Journal:  Radiologe       Date:  2013-03       Impact factor: 0.635

Review 7.  Renal denervation: intractable hypertension and beyond.

Authors:  Wassawon Ariyanon; Huijuan Mao; Zelal Adýbelli; Silvia Romano; Mariapia Rodighiero; Bernhard Reimers; Luigi La Vecchia; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2014-01-15       Impact factor: 2.041

Review 8.  Renal denervation therapy for resistant hypertension: a clinical update.

Authors:  C V S Ram; A S Kumar
Journal:  J Hum Hypertens       Date:  2014-03-06       Impact factor: 3.012

9.  Renal Denervation to Treat Heart Failure.

Authors:  Thomas E Sharp; David J Lefer
Journal:  Annu Rev Physiol       Date:  2020-10-19       Impact factor: 19.318

Review 10.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.